Neoplasm Of Mature T Cells Or Nk Cells C1334640
Cancers of mature immune cells including T cells and natural killer cells. Can cause skin lesions, lymph node swelling, or blood abnormalities. Treatment varies by subtype and may involve chemotherapy.
Key facts at a glance
- ICD-10
- C80.1
- ICD-11
- 2A00.0
- Body system
- oncologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Cutaneous skin lesions
(integumentary)Generalized symptoms
(oncologic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Lymphadenopathy
(lymphatic)Generalized pruritus
(integumentary)Systemic B symptoms (fever, night sweats, weight loss)
(systemic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Chemotherapy regimen
Combination chemotherapy is the primary treatment approach for mature T-cell or NK-cell neoplasms, typically involving agents such as cyclophosphamide, doxorubicin, vincristine, and steroids to target malignant lymphocytes.
Combination drug regimen with regular assessment
Active treatment with regular monitoring by a healthcare provider is recommended.
Additional treatment options
Hematopoietic stem cell transplantation
Autologous or allogeneic stem cell transplant may be considered for eligible patients, particularly those with relapsed or refractory disease, offering potential for long-term remission.
procedureRegular surveillance imaging and labs
Ongoing monitoring with PET-CT scans, blood work including CBC and LDH levels, and clinical assessments to evaluate treatment response and detect disease progression or relapse early.
monitoringInfection prevention measures
Implementation of protective hygiene practices including hand hygiene, avoiding crowds during immunosuppression, and prophylactic antibiotics as prescribed to reduce infection risk during treatment.
lifestyleSupportive integrative therapies
Acupuncture, massage therapy, and mind-body practices such as meditation may help manage treatment-related symptoms including fatigue, nausea, and pain while improving quality of life.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Neoplasm Of Mature T Cells Or Nk Cells C1334640?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalMedication Comparisons
Compare medications used to treat Neoplasm Of Mature T Cells Or Nk Cells C1334640. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy